文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA显像在转移性去势敏感性前列腺癌中的真实世界应用:CAPRI-3登记研究

Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2026-07-10

该回顾性研究基于荷兰CAPRI-3登记研究19家医院的3644例mCSPC患者,比较PSMA-PET/CT与传统影像的分期应用。PSMA-PET使用率从2016年8%升至2021年62%,PSMA-PET组患者更年轻、肿瘤负荷更低、总生存更长(78.3 vs 40.0个月),但需考虑分期迁移和选择偏倚。

要点

  • PSMA-PET/CT在mCSPC分期中的真实世界使用率从2016年8%升至2021年62%。
  • PSMA-PET组患者更年轻、高瘤负荷比例更低、仅淋巴结病变更多、异时性表现更常见。
  • PSMA-PET组中位总生存78.3个月,传统影像组40.0个月,但需警惕分期迁移与选择偏倚。

核心结论

  • 近年来PSMA-PET/CT用于mCSPC分期的比例呈上升趋势,所识别的人群具有更有利的疾病特征和预后。
  • 这种由分期迁移(Will Rogers现象)驱动的患者特征变化影响临床管理,使保守或靶向治疗的患者选择更精细。
  • 在PSMA-PET/CT时代比较生存结局时,必须考虑领先时间偏倚和选择偏倚。

研究设计与样本

  • 该研究为回顾性研究,纳入荷兰CAPRI-3登记研究中19家医院2016至2021年确诊的3644例mCSPC患者。
  • 分期依据诊断后90天内的影像检查分类为仅传统影像(CT、骨显像和/或MRI)或PSMA-PET(±传统影像)。

主要发现

  • 多数患者仅接受传统影像分期(63%),但PSMA-PET使用率从2016年8%升至2021年62%。
  • PSMA-PET分期患者更年轻(72 vs 76岁),高瘤负荷比例显著更低(27% vs 45%),仅淋巴结病变更多,异时性表现更常见(29% vs 22%,均P < 0.001)。
  • PSMA-PET组中42%接受ADT联合靶向治疗、23%接受ADT单药治疗,而传统影像组45%接受ADT单药治疗。
  • PSMA-PET组中位总生存显著更长(78.3 vs 40.0个月)。

临床怎么用

  • 在mCSPC分期中可考虑使用PSMA-PET/CT,其有助于识别疾病特征更有利的患者群体以指导治疗选择。
  • 解读PSMA-PET/CT时代的生存数据时,应意识到分期迁移和选择偏倚对预后比较的影响。

局限性

  • 该研究为回顾性设计,PSMA-PET组与传统影像组间的患者特征差异可能引入选择偏倚。
  • 分期迁移(Will Rogers现象)和领先时间偏倚可能影响两组生存结局的可比性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Since 2019, EAU guidelines recommend PSMA-PET/CT for staging high-risk prostate cancer. However, real-world data on its uptake and association with disease characteristics and outcomes in metastatic castration-sensitive prostate cancer (mCSPC) remains limited. We evaluated real-world PSMA-PET/CT use versus conventional imaging (CI). METHODS: This retrospective study included 3,644 mCSPC patients (2016-2021) from 19 hospitals in the Dutch CAPRI-3 registry. Staging within 90 days of diagnosis was classified as CI-only (CT, bone scintigraphy, and/or MRI) or PSMA-PET (± CI). RESULTS: Most patients were staged with CI-only (63%), but PSMA-PET use rose from 8% in 2016 to 62% in 2021. PSMA-PET-staged patients were younger (72 vs. 76 years) and had significantly lower tumour burden (27% vs. 45% high-volume), more nodal-only disease, and were more likely to have metachronous presentation (29% vs. 22%, all P < 0.001). In the PSMA-PET group, 42% received ADT plus targeted therapy and 23% ADT monotherapy (vs. 45% ADT monotherapy in CI-only). Median overall survival was significantly longer in the PSMA-PET cohort (78.3 vs. 40.0 months). CONCLUSION: There has been an increasing trend toward the use of PSMA PET/CT for staging mCSPC in recent years, identifying a population with more favourable disease characteristics and a more favourable prognosis. This shift in patient characteristics, driven by stage migration (the Will Rogers phenomenon), influences clinical management by enabling more refined patient selection for conservative or targeted therapies. Consequently, accounting for lead-time and selection bias is essential when comparing survival outcomes in the PSMA PET/CT era.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. van der Velden KJM, Bosch D, Vassilev Z, et al. Real-world use of PSMA imaging in metastatic castration-sensitive prostate cancer: Findings from the CAPRI-3 registry. Eur J Nucl Med Mol Imaging. 2026. PMID: 42429819. doi:10.1007/s00259-026-08050-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。